Teva and Amgen Settle Over Kidney Disease Patent Infringement

Health and Healthcare

Published: January 3, 2019 1:25 pm

Last Updated: January 31, 2020 2:33 am

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced on Thursday that it has settled with Amgen Inc. (NASDAQ: AMGN) for its treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.

The ongoing dispute regarding Teva’s generic cinacalcet HCI product is officially over. Teva and Amgen have been involved in patent infringement litigation, and Teva recently received approval for and launched its generic product in the United States.

According to the settlement, the litigation between the parties will be ended and Teva has agreed to stop selling its generic product until its license date in mid-year 2021, or earlier under certain circumstances.

Also, Teva will pay Amgen an undisclosed amount as part of the settlement. That amount and other terms of the settlement are confidential.

For some quick background: Cinacalcet is a calcium-sensing receptor agonist indicated for secondary HPT in adult patients with CKD on dialysis. It is also used for the treatment of hypercalcemia in adult patients with parathyroid carcinoma and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Shares of Teva were last seen up about 6% at $16.77, in a 52-week range of $14.59 to $25.96. The stock has a consensus analyst price target of $22.94.

Amgen was down nearly 1% at $190.42 a share, with a consensus price target of $204.52. The 52-week trading range is $163.31 to $210.19.

ALSO READ: Bull/Bear Outlook for 2019: How All 30 Dow Stocks Could Take the Market Up to 28,000

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.